Nov 4, 2020 by Brian Orelli, PhDCRISPR and Vertex Release Additional Data for Blood Disease TreatmentCTX001 continues to help patients with transfusion-dependent beta thalassemia and sickle cell disease.
Nov 2, 2020 by Brian Orelli, PhDCureVac Reports Early-Stage Data for Its Coronavirus Vaccine CandidateParticipants in the phase 1 clinical trial mounted an immune response after being inoculated with CVnCoV.
Nov 1, 2020 by Brian Orelli, PhD3 Reasons Pfizer and BioNTech's Coronavirus Vaccine Might Fail Even If It WorksClinical trials are tricky business.
Oct 30, 2020 by Brian Orelli, PhDDate Is Set for Merger Between Mylan and Pfizer's Upjohn UnitThe Federal Trade Commission has signed off on the deal.
Oct 29, 2020 by Brian Orelli, PhDHere's Why Abiomed Dropped TodayRevenue bounces back, but growth is still lacking.
Oct 29, 2020 by Brian Orelli, PhDModerna Expects First Look at Coronavirus Vaccine Candidate Data in NovemberThose early results could show that mRNA-1273 is effective enough against COVID-19 -- but if not, it will have several shots to hit its goal.
Oct 29, 2020 by Brian Orelli, PhDNovavax Sells 60 Million Doses of Its Coronavirus Vaccine to the U.K. GovernmentThe biotech will also set up a dedicated supply chain to produce NVX-CoV2372 for the U.K.
Oct 28, 2020 by Brian Orelli, PhDGilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment RemdesivirThe only FDA-approved treatment for COVID-19 added $873 million in the third quarter.
Oct 27, 2020 by Brian Orelli, PhDHere's Why Exact Sciences Stock Rocketed Higher TodaySolid earnings and a smart acquisition have investors hitting the buy button.
Oct 22, 2020 by Brian Orelli, PhDModerna Completes Enrollment in Its Late-Stage Coronavirus Vaccine TrialThere's nothing left to do but wait for the data.
Oct 21, 2020 by Brian Orelli, PhDHow Profitable Is Coronavirus Vaccine Development?The prices for the first batches of the vaccine have already been set.
Oct 20, 2020 by Brian Orelli, PhDIs Moderna Stock a Buy at This Price?Here's what it takes to justify the current valuation.
Oct 20, 2020 by Brian Orelli, PhDIs Gilead Sciences a Good Coronavirus Stock?Don't lose sight of the biotech's other approved drugs and pipeline candidates.
Oct 20, 2020 by Brian Orelli, PhDHow Monoclonal Antibodies Can Treat COVID-19 and What the Data Says About Vaccines1+1 could equal 3.
Oct 19, 2020 by Brian Orelli, PhDHow Should Investors Play COVID-19 Stocks?Treatments, vaccines, or both?
Oct 19, 2020 by Brian Orelli, PhD and Corinne Cardina JurneyTests, Treatments, Vaccines: Sorrento Therapeutics Is All In on COVID-19Will the lack of focus be the biotech's downfall?
Oct 19, 2020 by Brian Orelli, PhDIs Ionis Pharmaceuticals a Buy?Here's what it takes to justify the current valuation.
Oct 19, 2020 by Brian Orelli, PhD and Corinne Cardina JurneyCan Gilead Make Money From Its COVID-19 Treatment Remdesivir?Covering the company's costs should be easy, but total profits will be determined by the length of the pandemic.
Oct 19, 2020 by Brian Orelli, PhDHow Regeneron's Coronavirus Antibody Treatment Differs From Convalescent PlasmaManufacturing will play a big role in the eventual winner.
Oct 18, 2020 by Brian Orelli, PhD and Corinne Cardina JurneyWhat Should Investors Know About Eli Lilly's Coronavirus Antibody Treatments?The combination treatment looked better than the single-antibody treatment.
